Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
STRYKER PRODUCTOS
BIOSENSORS PRODUCTOS

NOTICIAS


27 junio 2012

Covidien launches campaign to increase awareness of pregnancy-related blood clots

Vascular NEWS

Covidien announced the launch of its 1 in 1,000 campaign to help educate women about the risk of pregnancy-related blood clots, one of the leading causes of maternal mortality in the developed world. The announcement was made at the 2012 annual meeting of the Association of Women s Health, Obstetric and Neonatal Nurses

26 junio 2012

Biodegradable Artery Graft Developed To Enhance Bypass Surgeries

MDT Medical Design Tecnology

With the University of Pittsburgh s development of a cell-free, biodegradable artery graft comes a potentially transformative change in coronary artery bypass surgeries: Within 90 days after surgery, the patient will have a regenerated artery with no trace of synthetic graft materials left in the body.

25 junio 2012

Kidney Damage from CV Surgery on the Rise

MEDPAGE TODAY. Crystal Phend, Senior Staff Writer

Acute kidney injury appears to be an increasing problem in cardiac and vascular surgeries, researchers found. Severe cases marked by need for acute dialysis after major elective surgery -- although rare -- rose year over year from a rate of 0.2% in 1995 to 0.6% in 2009, Amit X. Garg, MD, PhD, of Western University in London, Ontario, and colleagues reported.

25 junio 2012

FDA selects Medtronic stent for innovative programme

Vascular NEWS

The US Food and Drug Administration (FDA) recently selected an investigational stent graft for endovascular treatment of thoracic aortic aneurysms involving branch vessel. The device would be used inan early feasibility pilot programme.

19 junio 2012

Lobato: Sandwich Technique is a useful tool in the endovascular armamentarium

Vascular NEWS

The Sandwich Technique, developed to overcome current anatomical and device constraints, could expand the limits of endovascular aneurysm repair (EVAR) in a safe, easy to perform, and cost-effective manner, Armando Lobato, ICVE, Sao Paulo Vascular & Endovascular Surgery Institute, Beneficencia Portuguesa Hospital, Sao Paulo, Brazil, told delegates at the Society for Vascular Surgery Annual Meeting in Washington DC, USA.

19 junio 2012

MAQUET Cardiovascular Receives CE Mark For INTERGARD SYNERGY Vascular Graft

Healthcare Sales & Marketing Network

MAQUET Cardiovascular, LLC announced today that it has received CE mark for its INTERGARD SYNERGY vascular graft. This graft represents the next generation in antimicrobial grafts combining the well-known antimicrobial properties of silver acetate and triclosan. The INTERGARD SYNERGY graft will be commercially available immediately within countries that recognize the CE mark.

13 junio 2012

CONNECT II clinical trial completes enrolment

Vascular NEWS

Avinger has announced that it has successfully completed enrolment in its CONNECT II global clinical trial. A study focused on treatment of peripheral artery disease. CONNECT II is a prospective, multicentre, non-randomised global clinical study that evaluated 100 peripheral artery disease patients with femoropopliteal chronic total occlusion lesions at 15 hospital and clinic sites, including two in the European Union.

13 junio 2012

The DiamondbackT Orbital Atherectomy System provides patients with a cost effective treatment option that requires far fewer stent implants

MDT Medical Design Tecnology. BUSINESS WIRE

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), shared 12-month data from the COMPLIANCE 360 study of severely calcified above-the-knee lesions at the New Cardiovascular Horizons Annual Conference on Saturday, June 9, 2012. Dr. Barry Weinstock, Interventional Cardiologist, Orlando Regional Medical Center, Winter Park, Fla., presented data demonstrating positive outcomes and cost comparisons to the widely used percutaneous transluminal angioplasty (PTA).

08 junio 2012

Mechanochemical ablation shows 96% closure rate at two years

Vascular NEWS

At two years, mechanochemical ablation (MOCA) is as efficacious as current endothermal techniques without the need of tumescent anaesthesia and is more effective than reported results of foam sclerotherapy of the great saphenous vein. Steve Elias, who presented the first-in-man two-year results with the technique at the Vascular Annual Meeting (Washington DC, USA,7–9 June 2012), said that MOCA is another alternative modality for most incompetent great and small saphenous veins.

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.